Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
uniQure N.V.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 43.09 · gapped above the open, then crossed back over prior close. High/low 44.85 at 4:15 am ET, 42.80 at 3:15 pm ET.
uniQure N.V. has 9 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either uniQure N.V.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In August 2019, we amended our agreement with uniQure (the "Amended uniQure Agreement") and entered into a separate new collaboration and license agreement with uniQure (the "Second uniQure Agreement").”
FILING10-K0001193125-26-114075cik 0001650648disclosed by FDMT
“We and CSL Behring also entered into a development and commercial supply agreement, pursuant to which, among other things, we agreed to supply the product to CSL Behring.”
FILING10-K0001104659-26-021898cik 0001590560
“The use of AAV9 to deliver any sequence that affects the expression of the GRIK2 gene in humans has been exclusively licensed from Regenxbio Inc. ("Regenxbio").”
FILING10-K0001104659-26-021898cik 0001590560
“During the year ended December 31, 2023, we incurred expenses of $10.0 million related to the upfront consideration paid to Apic Bio for the global licensing rights to AMT-162.”
FILING10-K0001104659-26-021898cik 0001590560
“Our miQURE gene silencing platform, based on exclusively licensed technology from Cold Spring Harbor Laboratory ("CSHL"), is designed to degrade mutated genes without producing a "passenger strand" thereby mitigating potential off-target toxicity and induce silencing of the mutated gene in the entire target organ through secondary exosome-mediated delivery.”
FILING10-K0001104659-26-021898cik 0001590560
“In connection with the July 2024 closing of the Lexington Transaction, we and Genezen entered into certain additional agreements, including a commercial supply agreement pursuant to which Genezen will manufacture and supply our requirements of HEMGENIX pursuant to our manufacturing and supply obligations to CSL Behring, and development and other manufacturing services agreement pursuant to which Genezen will manufacture, supply and provide certain development services to support the requirements of our investigational gene therapy programs and for other discretionary services related to the manufacture of HEMGENIX, along with other customary agreements.”
FILING10-K0001104659-26-021898cik 0001590560
“In 2008, we entered into a license agreement with St. Jude Children's Research Hospital ("St. Jude"), which we amended in 2012.”
FILING10-K0001104659-26-021898cik 0001590560
“In the year ended December 31, 2025, we recognized $6.0 million in income related to a one-time sale of critical reagents to Genezen, compared to nil in the same periods in 2024 and 2023.”
FILING10-K0001104659-26-021898cik 0001590560
“In May 2023, uniQure biopharma entered into an agreement (the "Royalty Financing Agreement") with HemB SPV, L.P. to sell certain current and future royalties due to uniQure biopharma from CSL Behring under the CSL Behring Agreement by and between uniQure biopharma and CSL Behring from the net sales of HEMGENIX.”
FILING10-K0001104659-26-021898cik 0001590560
“In September 2025, we entered into the 2025 Amended Facility with Hercules for a $175.0 million senior secured term loan facility.”
FILING10-K0001104659-26-021898cik 0001590560
“In July 2025, we entered into a Sales Agreement with Leerink Partners LLC ("Leerink Partners") with respect to an at-the-market ("ATM") offering program, under which we may, from time to time and at our sole discretion, offer and sell through Leerink Partners, acting as agent, our ordinary shares, up to an aggregate offering of $200.0 million.”
FILING10-K0001104659-26-021898cik 0001590560
“In addition, in July 2024, as part of the closing of the asset purchase agreement among our affiliates, uniQure Inc. and uniQure biopharma B.V. ("uniQure biopharma"), and Genezen Holdings Inc. and its subsidiary Genezen MA, Inc. (together "Genezen") to sell certain assets and assume certain liabilities related to our former manufacturing facility and operations in Lexington, Massachusetts (the "Lexington Transaction"), we transferred the manufacturing and supply activities to Genezen such that Genezen manufactures and supplies CSL Behring's commercial demand for HEMGENIX on our behalf.”
FILING10-K0001104659-26-021898cik 0001590560
Watchlist prices, news filtered to it, and its next report on your desk.
QURE (uniQure N.V.) has 9 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: RGNX −8.52%, in healthcare.